Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction


Ozaydin M. , YUCEL H., KOCYIGIT S., ADALI M. K. , Aksoy F. , KAHRAMAN F., ...Daha Fazla

MEDICAL PRINCIPLES AND PRACTICE, cilt.25, ss.316-322, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 25 Konu: 4
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1159/000446184
  • Dergi Adı: MEDICAL PRINCIPLES AND PRACTICE
  • Sayfa Sayıları: ss.316-322

Özet

Objective: The aim of this study was to evaluate the efficacy of nebivolol, carvedilol or metoprolol succinate on the outcome of patients presenting with acute myocardial infarction (AMI) complicated by left ventricular dysfunction. Subjects and Methods: Patients (n = 172, aged 28-87 years) with AMI and left ventricular ejection fraction <= 0.45 were randomized to the nebivolol (n = 55), carvedilol (n = 60) and metoprolol succinate (n = 57) groups. Baseline demographic and clinical characteristics and composite event rates of nonfatal MI, cardiovascular mortality, hospitalization due to unstable angina pectoris or heart failure, stroke or revascularization during the 12-month follow-up were compared among the groups using the chi(2) test, t test or log-rank test as appropriate. Results: Baseline demographic and clinical characteristics were similar in the three groups. The composite end point during follow-up was lower in the patients treated with nebivolol than those treated with metoprolol (14.5 vs. 31.5%; p = 0.03). However, event rates were similar between the patients treated with carvedilol and those treated with the metoprolol (20.3 vs. 31.5%, p > 0.05) and between the patients treated with nebivolol and carvedilol (14.5 vs. 20.3%, p > 0.05). Conclusion: The patients treated with nebivolol experienced 12-month cardiovascular events at a lower rate than those treated with metoprolol succinate. However, event rates were similar between the carvedilol and the metoprolol succinate groups and between the nebivolol and the carvedilol groups. (C) 2016 S. Karger AG, Basel